Document is current

Article History

Received: 7 January 2020

Accepted: 9 July 2020

First Online: 14 August 2020

Ethics approval and consent to participate

: Three studies included were conducted in compliance with the Declaration of Helsinki and Good Clinical Practice Guidelines established by the International Conference Harmonisation. All subjects provided written informed consent.

: Not applicable

: Josef S. Smolen has received personal remuneration from AbbVie, Amgen, Astra-Zeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, ILTOO, Janssen, Lilly, MSD, Novartis-Sandoz, Novo-Nordisk, Pfizer, Roche, Samsung, Sanofi, and UCB and research funding from AbbVie, Janssen, Lilly, Novartis-Sandoz, Pfizer, and Roche. Michael E. Weinblatt has received research funding from Bristol-Myers Squibb, Crescendo Bioscience, and Sanofi/Regeneron; has served as a consultant and/or advisory board member for AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Corrona, GSK, Gilead, Lilly, Lycera, Merck, Novartis, Pfizer, Roche, Samsung Bioepis, and Set Point; and has financial interests/stock ownership in Lycera, Canfite, Scipher, and Vorso. Paul Emery has been a clinical trials investigator and advisor to Pfizer, MSD, AbbVie, Bristol-Myers Squibb, UCB, Roche, Novartis, Samsung, Sandoz, and Lilly and has received consulting fees from Bristol-Myers Squibb, AbbVie, Gilead, Pfizer, MSD, Novartis, Roche, and UCB; his employer has received research grants from AbbVie, Bristol-Myers Squibb, Pfizer, MSD, and Roche. Edward C. Keystone has received research funding from AbbVie, Amgen, Lilly, Gilead, Pfizer, PuraPharm, Sanofi, and Merck; has served as a consultant and/or advisory board member for AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celltrion, Crescendo Bioscience, Roche, Genentech, Gilead, Janssen, Lilly, Merck, Pfizer, Sandoz, Sanofi, and Samsung Bioepis; and has received speaker honoraria for Amgen, AbbVie, Bristol-Myers Squibb, Roche, Janssen, Merck, Pfizer, Sanofi, and UCB. Mark C. Genovese has received research funding from AbbVie and has received consulting fees from Samsung Bioepis, Merck, Abbvie, Amgen, and FKB. Gihyun Myung, Inyoung Baek, and Jeehoon Ghil are employees of Samsung Bioepis. Jung-Yoon Choe has no financial disclosures.